President & CEO Okamura, Naoki Primary Focus Lead (Blindness and Beyond) Jotaro Suzuki PLAY LIST from the beginning ACQUISITION OF IVERIC BIO @ @ ACQUISITION OF IVERIC BIO @ @ AGENDA TRANSACTION SUMMARY IVERIC BIO OVERVIEW STRATEGIC RATIONALE OF ACQUISITION AVACINCAPTAD PEGOL (ACP) OVERVIEW GEOGRAPHIC ATROPHY (GA) OVERVIEW SELECTED CLINICAL PIPELINE ASSETS TARGETING GEOGRAPHIC ATROPHY (GA) PIVOTAL TRIALS (GATHER1 AND GATHER2): OVERVIEW PIVOTAL TRIALS (GATHER1 AND GATHER2): EFFECT ON GA AREA PIVOTAL TRIALS (GATHER1 AND GATHER2): EFFECT ON VISION LOSS PIVOTAL TRIALS (GATHER1 AND GATHER2): SAFETY REVENUE CONTRIBUTION OF ACP (ILLUSTRATIVE) ESTABLISHING FOUNDATIONAL OPHTHALMOLOGY CAPABILITIES FINANCIAL CONSIDERATIONS APPENDIX MECHANISM OF ACTION ON THE FOREFRONT OF HEALTHCARE CHANGE Questions Questions 1 Questions 2 Questions 3 Questions 4 Questions 5 Questions 6 Questions 7 Questions 8 Questions 9 Questions 10 Questions 11 Questions 12 Questions 13 Back Next